Please login to the form below

Not currently logged in
Email:
Password:

Milestone names chief medical officer

Francis Plat bring experience from Merck, Daiichi-Sankyo, Novartis and BMS to the role

Cardiovascular specialist Milestone Pharmaceuticals has appointed experienced pharma researcher Dr Francis Plat as its new chief medical officer.

Dr Plat joins from Merck & Co where he was head of atherosclerosis and cardiovascular at the company's Merck Research Laboratories division.

His other big pharma experience includes roles at Daiichi-Sankyo, Novartis, and Bristol Myers Squibb, working on cardiovascular products including Efient, Diovan and Approvel.

As chief medical officer Dr Plat's responsibilities will include heading up the development of the company's lead product MSP-2017, which is under investigation as a treatment for paroxysmal supraventricular tachycardia – a condition defined by episodes of rapid heart rate.

Dr Plat commented that MSP-2017 promises a “paradigm shift” in the treatment of paroxysmal supraventricular tachycardia as it allows patients a far improved quality of life.

Milestone's CEO Philippe Douville said: "Dr Plat is the perfect candidate for our development program given his extensive cardiovascular drug development expertise developed during his career in large pharmaceutical companies."

28th July 2014

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
90TEN

90TEN is an award-winning healthcare communications consultancy that puts people at the heart of everything we do. Our Life.Changing. campaigns...

Latest intelligence

Measures for measures
Why pharma’s marketing metrics must close the loop...
Where next in Alzheimer’s disease R&D?
How past failures and emerging biology are reshaping drug development...
Brain scan
Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...

Infographics